• Nearly 30 years in the science and pharma fields


Scientist, Pharmaceutical Leadership, Project Management, Therapeutic and Technology Group Management, Pharmaceutical and Discovery Management (delivered 17 compounds in areas of Infectious Disease, Allergy Respiratory, Inflammation, Atherosclerosis, Cardiovascular, Cystic Fibrosis), Licensing, Portfolio Analysis, Restructuring, Infrastructure Development, Presentations, Aggressive Time Lines, Patents (28), Publications (29), Abstracts (31).

Post-doc, Yale University

PhD, Organic Chemistry, Wayne State University in Detroit, MI


Independent Consultant – Brad Tait Enterprise LLC

Provide pharmaceutical consulting in the areas of medicinal chemistry strategy, chemistry intellectual property, licensing, due diligence, project management, and drug discovery management. Experienced in enzymes, proteases, kinases, GPCR, NHR, ion channels, and unknown mechanism.

Vice President – Proteostasis Therapeutics Inc.

As a Cystic Fibrosis Leader, led the overall Cystic Fibrosis strategy and team, built a cohesive team that delivered quality candidates on aggressive time lines, and led the forward planning from pre-clinical toxicology to Phase II.

As Vice President, Chemistry, developed strategy for: Cystic Fibrosis, Alzheimer’s, Parkinson’s, and Huntington’s disease. Hired internal chemistry staff and managed the external contract chemists. Built infrastructure: chemistry labs, a high-quality compound library, and corporate database. Evaluated external opportunities resulting in three licensed projects. Presented PTI science to investors, foundations, and collaborators resulting in agreements with Élan and Cystic Fibrosis Foundation Therapeutics.

Senior Director – Pfizer Pharmaceuticals Inc.

As Senior Director Cardiovascular / Atherosclerosis Chemistry / PET / PSL, delivered multiple clinical candidates per year targeting hypertension, thrombosis, dyslipidemia, and vessel wall. Led a group of 35-50 internal and 0-15 contract chemists (one to three directors). Impacted licensing team strategy by evaluating target and compound opportunities. Implemented changes in PSL and PET imaging affording improved spirit and integration. Restructured CV/Athero portfolio, resulting in the sustained delivery of clinical candidates by decisive experiments, stopping programs, changing project leaders, and adding targets.

Assistant Director Inflammation Chemistry – Parallel Synthesis Lab

Delivered a clinical candidate per year targeting osteoarthritis and rheumatoid arthritis. Managed group of ~30 chemists (11 PhD). Mentored a top performer that led to a transition into a management role. Co-led inflammation global management team that improved communication and alignment. Improved the zone parallel synthesis lab impact by ensuring full integration into project teams. Stopped a compound from entering development due to unnecessary safety risks. Impacted the licensing team by identifying and triaging opportunities, including due diligence.